Trade Mark Journal No.2025/033 15 August 2025

UK00004242910 1 August 2025 (5)

ACSTRYVE

International priority date claimed: 5 February 2025 (United States of America) (99029897)

Class 5: Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; diagnostic radiopharmaceutical preparations.

RayzeBio, Inc.

Representative: Sipara Limited